{"id":46009,"date":"2015-09-01T17:00:47","date_gmt":"2015-09-01T16:00:47","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/closing-regulatory-gaps-new-ground-rules-for-platelet-rich-plasma\/"},"modified":"2026-02-11T17:38:10","modified_gmt":"2026-02-11T16:38:10","slug":"closing-regulatory-gaps-new-ground-rules-for-platelet-rich-plasma","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/en\/closing-regulatory-gaps-new-ground-rules-for-platelet-rich-plasma\/","title":{"rendered":"Closing regulatory gaps: new ground rules for platelet-rich plasma"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text css=””]<\/p>\n

Abstract<\/h3>\n
\n
\n

The Spanish Agency of Medicines and Medical Devices (AEMPS) has drawn up a comprehensive report and resolution that regulates for the first time the use of platelet-rich plasma (PRP) as a human-use medicinal product. This regulatory framework offers emerging challenges to adapt the use of PRP to the new requirements of safety and efficacy. The heterogeneity of the different products can hinder their regulation, which today differs substantially in the different worldwide regulatory frameworks.<\/p>\n<\/div>\n

Keywords:\u00a0<\/strong>medicinal product; platelet-rich plasma; regulatory framework.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row][vc_column]\n Access the full article<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Trends Biotechnol. 2015 Sep;33(9):492-5.<\/strong>
\nThe Spanish Agency of Medicines and Medical Devices (AEMPS) has drawn up a comprehensive report and resolution that regulates for the first time the use of platelet-rich plasma (PRP) as a human-use medicinal product. This regulatory framework offers emerging challenges to adapt the use of PRP to the new requirements of safety and efficacy. The heterogeneity of the different products can hinder their regulation, which today differs substantially in the different worldwide regulatory frameworks.<\/p>\n","protected":false},"author":2002,"featured_media":46002,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[150],"tags":[],"class_list":["post-46009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regenerative-medicine"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/posts\/46009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/comments?post=46009"}],"version-history":[{"count":1,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/posts\/46009\/revisions"}],"predecessor-version":[{"id":46010,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/posts\/46009\/revisions\/46010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/media\/46002"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/media?parent=46009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/categories?post=46009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/en\/wp-json\/wp\/v2\/tags?post=46009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}